Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics.
The last earnings update was 49 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Celldex Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Celldex Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Celldex Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Celldex Therapeutics's revenue is expected to grow by 4.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Celldex Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Celldex Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Celldex Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Celldex Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Celldex Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Celldex Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. Mr. Marucci Founded Celldex Therapeutics Inc. in May 2003. Mr. Marucci served as a Treasurer of BioNJ Inc. until 2010. He served as an Interim Chief Executive Officer and Interim President of Celldex Therapeutics Inc., from May 2008 to September 2008 and its Executive Vice President of Corporate Development from July 2008 to October 2008. Mr. Marucci served as the Chief Operating Officer, Principal Accounting Officer and Executive Vice President of Celldex Therapeutics, Inc., and its Executive Vice President of Corporate Development since March 2008 and Acting Chief Executive Officer since October 2007. He served as the Chief Financial Officer, Treasurer and Secretary of Celldex Therapeutics, Inc. since May 2003. Mr. Marucci held a series of senior financial positions at Medarex from December 1998 to May 2003. He served as a Treasurer of Medarex, Inc. (now a part of Bristol-Myers Squibb Co.) from December 1998 to March 2004. Mr. Marucci held a series of Senior Financial President of Medarex since December 1998. He has been a Director of Celldex Therapeutics Inc., since December 4, 2008. Mr. Marucci is a member of the Board of the College of Business and Public Management at Kean University. Mr. Marucci serves as a Trustee of BioNJ Inc. Mr. Marucci holds an MBA from Columbia University and his E.M.H.L. from Brown University.
Anthony's compensation has been consistent with company performance over the past year.
Anthony's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Celldex Therapeutics management team is about average.
Chief Product Development Officer & Senior VP
Chief Commercial Officer & Senior VP
Senior Vice President of Corporate Affairs & Administration
Chief Business Officer & Senior VP
Senior Vice President of Regulatory Affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Celldex Therapeutics board of directors is about average.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, currently being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in multiple types of solid tumors and B cell lymphomas; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-301, a dendritic cell growth factor; and Varlilumab, an immune modulating antibody targeting CD27 designed to enhance a patient's immune response. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.